Rekvina Laboratories EGM Greenlights Share Capital Hike, Preferential Share Sales

All six resolutions presented at Rekvina Laboratories Ltd's Extra-Ordinary General Meeting (EGM) on April 10, 2026, were passed unanimously by shareholders. Resolution 6, concerning preferential share issuance for cash, received 3,164,996 votes in favor, with 100% of votes polled supporting all proposals.

What Happened

Rekvina Laboratories Ltd convened its EGM on April 10, 2026. Shareholders gave overwhelming support to all six resolutions. These included significant approval to increase the company's authorized share capital and make updates to its company charter. Shareholders also sanctioned deals involving related parties and approved specific financial activities beyond standard limits.

The company secured backing for issuing equity shares through preferential allotment, covering both cash and non-cash considerations.

Why It Matters

These approvals give Rekvina's management the go-ahead to raise capital and restructure finances. This comes at a crucial time, potentially supporting recent strategic moves like the planned acquisition of Radiant Parenterals Ltd. The successful passing of resolutions for preferential share issuance is a key step toward strengthening the company's financial base and enabling future growth.

Company Background

Rekvina Laboratories, a pharmaceutical company established in 1988, has faced financial challenges, marked by consistent losses and low revenues in recent years. The company has also dealt with past regulatory scrutiny, including a trading suspension for non-compliance.

Recently, three acquirers initiated an open offer for 26% of the company's shares at ₹10 each. This followed Rekvina's decision to acquire Radiant Parenterals Ltd. for approximately ₹4.63 Crore through a share swap.

What Changes Now

Shareholder approval allows Rekvina Laboratories to legally:

• Increase its authorized share capital.
• Alter its company charter.
• Proceed with issuing shares via preferential allotment (cash and non-cash).
• Undertake sanctioned related party transactions and financial commitments.

Risks to Watch

Shareholders gave their nod for the capital raise, with promoter group interest in approving related party transactions noted. While Resolution 4, like all others, passed with 100% of votes polled, ongoing transparency and adherence to arm's length principles in such deals will be critical. Rekvina's history of financial struggles and a past trading suspension remain factors to monitor.

Company Context

Rekvina operates in the small-cap pharmaceutical sector, navigating financial challenges. Unlike larger, established players, its immediate focus is on restructuring and capital enhancement to overcome these hurdles.

Financial Metrics

• For the nine months ended December 31, 2025, Rekvina reported total revenue of ₹54.18 lakhs and a net loss of ₹19.42 lakhs (Standalone).
• The company's authorized share capital is ₹3.50 Crore, divided into 70,00,000 equity shares of ₹5 face value each.

What to Track Next

• Execution of the approved preferential share issuances and capital increase.
• Progress on the acquisition of Radiant Parenterals Ltd.
• The outcome and timeline of the ongoing open offer for Rekvina's shares.
• Management's strategy to leverage new capital for financial turnaround and growth.